Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Design Therapeutics, Inc.DSGN · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required |
| Reliability | 0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| Peer failure rate | 1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $120M to $591M assetstotal assets $226.2M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | short runway, thin data, degenerate inputsnot computable: fortress balance sheet |
| Inputs computable | 6 of 14 |
| Graded from | filings received through Mar 9, 2026214 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $11.472026-10-08; market equity $718.1M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 9, 2026; the document on sec.gov.
As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, “Design,” “our company,” “we,” “us,” and “our” refer to Design Therapeutics, Inc., a Delaware corporation. We are a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC® molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 57.0 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (6.5%) | [1,4-6] | (6.6%) | 57.0 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 10.7 | |||||||
| Twelve-month failure probability | 0.04% | 0.07% | 22.7 | 248 | 2026-06-30 | ||
| Altman Z double-prime | 15.76 | [1,7-12] | (0.31) | 4.1 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| one or more required annual facts are missing | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| one or more required annual facts are missing | |||||||
| Current ratio | 17.14x | [7-8] | 2.96x | 5.3 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 61.0 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| four annual observations are required; found 2 | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| one or more required annual facts are missing | |||||||
| Asset growth, three years | (12.8%) | [1,6,13-14] | 2.1% | 72.7 | 704 | 2025-12-31 | |
| Net share issuance, one year | 8.6% | [15-16] | 2.5% | 49.3 | 634 | 2026-03-02 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | 100.4% | 8.0% | 88 | hotter than 88 of 100 peers |
| Distance from 52-week high | (27.9%) | (31.4%) | 55 | closer to its high than 55 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | (7.6%) | (1.0%) | 36 | pricier than 64 of 100 peers |
| Book value to price | 0.28 | 0.28 | 50 | pricier than 50 of 100 peers |
| Sales to price | 0.00 | 0.31 | 0 | pricier than 100 of 100 peers |
| Composite equity issuance, five years | not computable | 20.3% | a share count from five years earlier is required | |
| Relative strength against the sector, log excess return | 0.48 | (0.14) | 88 | ahead of 88 of 100 peers |
Inputs: market equity $719.1M; EBIT -$79.5M; free cash flow -$54.6M; book equity $201.9M; sales $0; cash $12.9M[17].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (27.7%) | ✗ fail[4,6] |
| Operating cash flow above zero | -$54.4M | ✗ fail[5] |
| Return on assets improved | (10.6 pts) | ✗ fail[4,6,13,18] |
| Operating cash flow exceeds net income | $15.4M | ✓ pass[4-5] |
| Long-term leverage fell | n/a[1,6,13] | |
| Current ratio improved | (1,217.1 pts) | ✗ fail[7-8,19-20] |
| No new shares issued | 8.6% | ✗ fail[15-16] |
| Gross margin improved | n/a | |
| Asset turnover improved | 0.0 pts | ✗ fail[2,6,13,21] |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $226.2M | 2025-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:Revenues | $0 | 2025-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $12.9M | 2026-06-30 | 2026-08-03 | 10-Q | filing · viewer · series |
| 4 | net income | us-gaap:NetIncomeLoss | -$69.8M | 2025-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$54.4M | 2025-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 6 | assets | us-gaap:Assets | $252.1M | 2024-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 7 | current assets | us-gaap:AssetsCurrent | $223.8M | 2025-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 8 | current liabilities | us-gaap:LiabilitiesCurrent | $13.1M | 2025-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 9 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$297.0M | 2025-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 10 | operating income | us-gaap:OperatingIncomeLoss | -$79.5M | 2025-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 11 | book equity | us-gaap:StockholdersEquity | $212.5M | 2025-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 12 | liabilities | us-gaap:Liabilities | $13.7M | 2025-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 13 | assets | us-gaap:Assets | $289.6M | 2023-12-31 | 2025-03-10 | 10-K | filing · viewer · series |
| 14 | assets | us-gaap:Assets | $341.1M | 2022-12-31 | 2024-03-19 | 10-K | filing · viewer · series |
| 15 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 61,672,279 | 2026-03-02 | 2026-03-09 | 10-K | filing · viewer · series |
| 16 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 56,762,678 | 2025-03-06 | 2025-03-10 | 10-K | filing · viewer · series |
| 17 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 62,581,651 | 2026-07-29 | 2026-08-03 | 10-Q | filing · viewer · series |
| 18 | net income | us-gaap:NetIncomeLoss | -$49.6M | 2024-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 19 | current assets | us-gaap:AssetsCurrent | $248.0M | 2024-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 20 | current liabilities | us-gaap:LiabilitiesCurrent | $8.5M | 2024-12-31 | 2026-03-09 | 10-K | filing · viewer · series |
| 21 | revenue | us-gaap:Revenues | $0 | 2024-12-31 | 2025-03-10 | 10-K | filing · viewer · series |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$32.0M | 2026-06-30 | 2026-08-03 | 10-Q | filing · viewer · series |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$16.4M | 2026-03-31 | 2026-04-28 | 10-Q | filing · viewer · series |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$42.4M | 2025-09-30 | 2025-11-05 | 10-Q | filing · viewer · series |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$31.2M | 2025-06-30 | 2026-08-03 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.